BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 2012;81:2417-22. [PMID: 21899970 DOI: 10.1016/j.ejrad.2011.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Vermersch M, Mulé S, Chalaye J, Galletto Pregliasco A, Emsen B, Amaddeo G, Monnet A, Stemmer A, Baranes L, Laurent A, Leroy V, Itti E, Luciani A. Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients. J Clin Med 2021;10:4017. [PMID: 34501465 DOI: 10.3390/jcm10174017] [Reference Citation Analysis]
2 Cárdenes HR, Lasley F. Primary Liver Cancer. In: Lo SS, Teh BS, Lu JJ, Schefter TE, editors. Stereotactic Body Radiation Therapy. Berlin: Springer Berlin Heidelberg; 2012. pp. 163-82. [DOI: 10.1007/174_2012_548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Parikh U, Marcus C, Sarangi R, Taghipour M, Subramaniam RM. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. PET Clin. 2015;10:327-343. [PMID: 26099670 DOI: 10.1016/j.cpet.2015.03.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
4 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
5 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
6 Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol 2016; 22(12): 3325-3334 [PMID: 27022214 DOI: 10.3748/wjg.v22.i12.3325] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
7 Kim YI, Paeng JC, Cheon GJ, Suh KS, Lee DS, Chung JK, Kang KW. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT. J Nucl Med. 2016;57:1045-1051. [PMID: 26985057 DOI: 10.2967/jnumed.115.170076] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
8 Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. J Nucl Med. 2013;54:1710-1716. [PMID: 23970365 DOI: 10.2967/jnumed.112.119370] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
9 Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016; 22(23): 5384-5392 [PMID: 27340354 DOI: 10.3748/wjg.v22.i23.5384] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
10 Ye YF, Wang W, Wang T, Yu J, Geng L, Yu SF, Yan S, Zheng SS. Role of [18F] fludeoxyglucose positron emission tomography in the selection of liver transplantation candidates in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2017;16:257-263. [PMID: 28603093 DOI: 10.1016/s1499-3872(17)60011-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Na SJ, Oh JK, Hyun SH, Lee JW, Hong IK, Song BI, Kim TS, Eo JS, Lee SW, Yoo IR, Chung YA, Yun M. 18F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort Study. J Nucl Med. 2017;58:730-736. [PMID: 27789714 DOI: 10.2967/jnumed.116.182022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
12 Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol 2013;59:367-74. [PMID: 23557870 DOI: 10.1016/j.jhep.2013.03.026] [Cited by in Crossref: 75] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
13 Schierz J, Opfermann T, Steenbeck J, Lopatta E, Settmacher U, Stallmach A, Marlowe RJ, Freesmeyer M. Early Dynamic 18 F-FDG PET to Detect Hyperperfusion in Hepatocellular Carcinoma Liver Lesions. J Nucl Med 2013;54:848-54. [DOI: 10.2967/jnumed.112.113936] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
14 Filippi L, Schillaci O, Bagni O. Recent advances in PET probes for hepatocellular carcinoma characterization. Expert Review of Medical Devices 2019;16:341-50. [DOI: 10.1080/17434440.2019.1608817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
15 Lin CY, Liao CW, Chu LY, Yen KY, Jeng LB, Hsu CN, Lin CL, Kao CH. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Clin Nucl Med. 2017;42:e183-e187. [PMID: 28114226 DOI: 10.1097/rlu.0000000000001545] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
16 Dubash SR, Idowu OA, Sharma R. The emerging role of positron emission tomography in hepatocellular carcinoma. Hepat Oncol. 2015;2:191-200. [PMID: 30190998 DOI: 10.2217/hep.15.6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, Guan Y, Jia H, Chen J, Lu L, Xie F, Qin L. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. Front Oncol 2021;11:693640. [PMID: 34249748 DOI: 10.3389/fonc.2021.693640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Donswijk ML, Hess S, Mulders T, Lam MG. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies. PET Clin 2014;9:421-41, v-vi. [PMID: 26050945 DOI: 10.1016/j.cpet.2014.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
19 Abouzied MM, Alhinti N, AlMuhaideb A, Al Sugair AS, Al Qahtani M. Extrahepatic metastases from hepatocellular carcinoma: multimodality image evaluation. Nucl Med Commun 2021;42:583-91. [PMID: 33625188 DOI: 10.1097/MNM.0000000000001380] [Reference Citation Analysis]
20 Lu RC, She B, Gao WT, Ji YH, Xu DD, Wang QS, Wang SB. Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2019; 25(32): 4682-4695 [PMID: 31528094 DOI: 10.3748/wjg.v25.i32.4682] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
21 Tong AK, Tham WY, Too CW, Tai DW, Chow PK, Ng DC. Molecular Imaging and Therapy of Liver Tumors. Semin Nucl Med 2020;50:419-33. [PMID: 32768006 DOI: 10.1053/j.semnuclmed.2020.04.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
23 Eo JS, Paeng JC, Lee DS. Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation. World J Gastroenterol 2014; 20(18): 5375-5388 [PMID: 24833867 DOI: 10.3748/wjg.v20.i18.5375] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 Wu B, Zhang Y, Tan H, Shi H. Value of 18F-FDG PET/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:2430-5. [PMID: 30944961 DOI: 10.1007/s00261-019-01997-2] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Lee TK, Kwon J, Na KS, Jeong HS, Hwang H, Oh PS, Kim DH, Jang KY, Lim ST, Sohn MH, Jeong HJ. Evaluation of Selective Arterial Embolization Effect by Chitosan Micro-Hydrogels in Hindlimb Sarcoma Rodent Models Using Various Imaging Modalities. Nucl Med Mol Imaging 2015;49:191-9. [PMID: 26279692 DOI: 10.1007/s13139-014-0316-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
27 Hoogenboom TC, Thursz M, Aboagye EO, Sharma R. Functional imaging of hepatocellular carcinoma. Hepat Oncol 2016;3:137-53. [PMID: 30191034 DOI: 10.2217/hep-2015-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Sun DW, An L, Wei F, Mu L, Shi XJ, Wang CL, Zhao ZW, Li TF, Lv GY. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis. Abdom Radiol (NY). 2016;41:33-41. [PMID: 26830609 DOI: 10.1007/s00261-015-0603-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
29 Fraum TJ, Ludwig DR, Hope TA, Fowler KJ. PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects. Gastroenterol Clin North Am 2018;47:691-714. [PMID: 30115444 DOI: 10.1016/j.gtc.2018.04.011] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Abdelhalim H, Houseni M, Elsakhawy M, Abd Elbary N, Elabd O. Role of 18F-FDG PET-CT in initial staging of hepatocellular carcinoma and its impact on changing clinical decision. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-019-0012-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Takemura N, Hasegawa K, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Surgical resection of peritoneal or thoracoabdominal wall implants from hepatocellular carcinoma. Br J Surg. 2014;101:1017-1022. [PMID: 24828028 DOI: 10.1002/bjs.9489] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
32 Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Uchiyama K. Surgical treatment of extrahepatic recurrence of hepatocellular carcinoma. Langenbecks Arch Surg. 2014;399:1057-1064. [PMID: 25030500 DOI: 10.1007/s00423-014-1230-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
33 Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018;7:235-260. [PMID: 30319983 DOI: 10.1159/000488035] [Cited by in Crossref: 186] [Cited by in F6Publishing: 196] [Article Influence: 46.5] [Reference Citation Analysis]
34 Bailly M, Venel Y, Orain I, Salamé E, Ribeiro MJ. 18F-FDG PET in Liver Transplantation Setting of Hepatocellular Carcinoma: Predicting Histology? Clin Nucl Med 2016;41:e126-9. [PMID: 26545024 DOI: 10.1097/RLU.0000000000001040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
35 Abouzied MM, Fathala A, AlMuhaideb A, Almanea H, Al-Sugair AS, AlSkaff R, Al-Qahtani MH. Gastric wall metastases from hepatocellular carcinoma: case report and review of the literature. Radiol Case Rep 2021;16:550-4. [PMID: 33384755 DOI: 10.1016/j.radcr.2020.12.047] [Reference Citation Analysis]
36 Levy CS, Costa FGB, Faria DP, Stefano JT, Cogliati B, Oliveira CP. 18F-FDG PET/CT as an assessment tool of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease development in experimental model.Arq Gastroenterol. 2019;56:45-50. [PMID: 31141073 DOI: 10.1590/S0004-2803.201900000-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Ochodo EA, van Enst WA, Naaktgeboren CA, de Groot JA, Hooft L, Moons KG, Reitsma JB, Bossuyt PM, Leeflang MM. Incorporating quality assessments of primary studies in the conclusions of diagnostic accuracy reviews: a cross-sectional study. BMC Med Res Methodol 2014;14:33. [PMID: 24588874 DOI: 10.1186/1471-2288-14-33] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
38 Ding E, Lu D, Wei L, Feng X, Shen J, Xu W. Predicting tumor recurrence using metabolic indices of 18F-FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma. Oncol Lett 2020;20:1245-55. [PMID: 32724365 DOI: 10.3892/ol.2020.11681] [Reference Citation Analysis]
39 Rydzak C, Chauhan A, Gupta N, Chuang HH, Rohren EM, Bhosale PR. Fat-Containing Hypermetabolic Masses on FDG PET/CT: A Spectrum of Benign and Malignant Conditions. AJR Am J Roentgenol 2016;207:1095-104. [PMID: 27490138 DOI: 10.2214/AJR.16.16066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Lee TK, Na KS, Kim J, Jeong HJ. Establishment of animal models with orthotopic hepatocellular carcinoma. Nucl Med Mol Imaging 2014;48:173-9. [PMID: 25177373 DOI: 10.1007/s13139-014-0288-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
41 Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013;12:530-547. [PMID: 23400006 DOI: 10.1102/1470-7330.2012.0044] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
42 Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019;14:437-45. [DOI: 10.1016/j.cpet.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol 2016;65:1017-30. [PMID: 27395013 DOI: 10.1016/j.jhep.2016.06.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
44 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6:387-396. [PMID: 29312973 DOI: 10.21037/hbsn.2017.11.01] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
45 Ramachandran Nair AV, Pratap T, Mahadevan P, Mukkada RJ, Yadav A, Senthil R. 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Detected Inguinal Lymph Nodal Metastasis from Hepatocellular Carcinoma. Indian J Nucl Med 2021;36:233-4. [PMID: 34385808 DOI: 10.4103/ijnm.ijnm_241_20] [Reference Citation Analysis]
46 Xia F, Wu L, Lau WY, Li G, Huan H, Qian C, Ma K, Bie P. Positive lymph node metastasis has a marked impact on the long-term survival of patients with hepatocellular carcinoma with extrahepatic metastasis. PLoS One. 2014;9:e95889. [PMID: 24760012 DOI: 10.1371/journal.pone.0095889] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
47 Lee JW, Hwang SH, Kim DY, Han KH, Yun M. Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. Clin Nucl Med. 2017;42:e35-e40. [PMID: 27775940 DOI: 10.1097/rlu.0000000000001422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
48 Rahim EA, Noh MS, Ngah NA, Suraini MS, Yusof MM. Hepatocellular carcinoma with disseminated skeletal muscle metastasis. Acta Radiol Open 2017;6:2058460117716705. [PMID: 28811928 DOI: 10.1177/2058460117716705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Hayakawa N, Nakamoto Y, Nakatani K, Hatano E, Seo S, Higashi T, Saga T, Uemoto S, Togashi K. Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients. Int J Clin Oncol. 2014;19:1020-1028. [PMID: 24366329 DOI: 10.1007/s10147-013-0653-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
50 Ping B, Tsuno S, Wang X, Ishihara Y, Yamashita T, Miura K, Miyoshi F, Shinohara Y, Matsuki T, Tanabe Y, Tanaka N, Ogawa T, Shiota G, Miura N. Comparative study of ¹⁸F-FDG-PET/CT imaging and serum hTERT mRNA quantification in cancer diagnosis. Cancer Med 2015;4:1603-11. [PMID: 26275387 DOI: 10.1002/cam4.508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
51 Florimonte L, Iavarone M, Castellani M, Longo M, Pallotti F, Maffioli L, Orunesu E, Benti R. Uncommon extrahepatic metastases from hepatocellular carcinoma. Hepatology 2017;66:986-8. [PMID: 28295419 DOI: 10.1002/hep.29147] [Reference Citation Analysis]
52 Castello A, Lopci E. Imaging HCC treated with radioembolization: review of the literature and clinical examples of choline PET utility. Clin Transl Imaging 2020;8:377-92. [DOI: 10.1007/s40336-020-00384-y] [Reference Citation Analysis]
53 Liao X, Wei J, Li Y, Zhong J, Liu Z, Liao S, Li Q, Wei C. 18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma. Medicine (Baltimore). 2018;97:e11970. [PMID: 30142825 DOI: 10.1097/md.0000000000011970] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Fosse P, Girault S, Hoareau J, Testard A, Couturier O, Morel O. Unusual uptake of 18FDG by a hepatic adenoma. Clin Nucl Med. 2013;38:135-136. [PMID: 23334131 DOI: 10.1097/rlu.0b013e318279b95a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
55 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
56 Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, Zohar Y, Shibolet O, Even-Sapir E. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study. J Nucl Med. 2019;60:185-191. [PMID: 30002112 DOI: 10.2967/jnumed.118.214833] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]